MCID: LKM004
MIFTS: 35

Leukemia, B-Cell, Chronic

Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases, Skin diseases

Aliases & Classifications for Leukemia, B-Cell, Chronic

MalaCards integrated aliases for Leukemia, B-Cell, Chronic:

Name: Leukemia, B-Cell, Chronic 53
Chronic Lymphocytic Leukemia 72
Chronic B-Cell Leukemia 53

Classifications:



External Ids:

UMLS 72 C0023434

Summaries for Leukemia, B-Cell, Chronic

MalaCards based summary : Leukemia, B-Cell, Chronic, also known as chronic lymphocytic leukemia, is related to leukemia, chronic lymphocytic and hairy cell leukemia, and has symptoms including fatigue, angina pectoris and edema. An important gene associated with Leukemia, B-Cell, Chronic is ATM (ATM Serine/Threonine Kinase). The drugs alemtuzumab and Valganciclovir have been mentioned in the context of this disorder. Affiliated tissues include b cells, t cells and bone.

Related Diseases for Leukemia, B-Cell, Chronic

Graphical network of the top 20 diseases related to Leukemia, B-Cell, Chronic:



Diseases related to Leukemia, B-Cell, Chronic

Symptoms & Phenotypes for Leukemia, B-Cell, Chronic

UMLS symptoms related to Leukemia, B-Cell, Chronic:


fatigue, angina pectoris, edema, chest pain

Drugs & Therapeutics for Leukemia, B-Cell, Chronic

Drugs for Leukemia, B-Cell, Chronic (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 471)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
alemtuzumab Approved, Investigational Phase 4 216503-57-0
2
Valganciclovir Approved, Investigational Phase 4 175865-60-8 64147
3
Heparin Approved, Investigational Phase 4 9005-49-6 46507594 772
4
Acetaminophen Approved Phase 4 103-90-2 1983
5
Promethazine Approved, Investigational Phase 4 60-87-7 4927
6
Diphenhydramine Approved, Investigational Phase 4 58-73-1, 147-24-0 3100
7
Pancrelipase Approved, Investigational Phase 4 53608-75-6
8
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
9
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
10
Chlorambucil Approved Phase 4 305-03-3 2708
11 Vaccines Phase 4
12 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
13 Cyclosporins Phase 4
14 Thymoglobulin Phase 4
15 Antilymphocyte Serum Phase 4
16 calcium heparin Phase 4
17 pancreatin Phase 4
18 Hydrocortisone 17-butyrate 21-propionate Phase 4
19 Hydrocortisone hemisuccinate Phase 4
20 Hematinics Phase 4
21 Epoetin alfa Phase 4 113427-24-0
22
Pixantrone Approved, Investigational Phase 3 144510-96-3
23
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
24
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
25
Cladribine Approved, Investigational Phase 3 4291-63-8 20279
26
Darbepoetin alfa Approved, Investigational Phase 3 11096-26-7, 209810-58-2
27
Guaifenesin Approved, Investigational, Vet_approved Phase 3 93-14-1 3516
28
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
29
Dalteparin Approved Phase 3 9005-49-6
30
Caspofungin Approved Phase 3 179463-17-3, 162808-62-0 468682 2826718
31
Tazobactam Approved Phase 3 89786-04-9 123630
32
Piperacillin Approved Phase 3 66258-76-2 43672
33
Vancomycin Approved Phase 3 1404-90-6 441141 14969
34
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
35
Morphine Approved, Investigational Phase 3 57-27-2 5288826
36
Ribavirin Approved Phase 3 36791-04-5 37542
37
Palivizumab Approved, Investigational Phase 3 188039-54-5
38
Itraconazole Approved, Investigational Phase 3 84625-61-6 55283
39
Captopril Approved Phase 3 62571-86-2 44093
40
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
41
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
42
Acyclovir Approved Phase 3 59277-89-3 2022
43
Triamcinolone Approved, Vet_approved Phase 3 124-94-7 31307
44
Obinutuzumab Approved, Investigational Phase 3 949142-50-1
45
Melphalan Approved Phase 2, Phase 3 148-82-3 460612 4053
46
Thiotepa Approved, Investigational Phase 2, Phase 3 52-24-4 5453
47
Carboplatin Approved Phase 2, Phase 3 41575-94-4 10339178 498142 38904
48
Phylloquinone Approved, Investigational Phase 3 84-80-0
49
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
50
Idelalisib Approved Phase 3 870281-82-6

Interventional clinical trials:

(show top 50) (show all 1331)
# Name Status NCT ID Phase Drugs
1 A Multicenter, Open-Label Study of Nipent, Cytoxan and Rituxan in Patients With Previously Untreated or Treated Chronic Lymphocytic Leukemia. Unknown status NCT00131313 Phase 4 Nipent, Cytoxan, Rituxan
2 Evaluation of the Immune Response After Vaccination Against Hepatitis B in Patients With Indolent Lymphoproliferative Disorders With no Treatment. Unknown status NCT01698866 Phase 4
3 1-Year Longitudinal Follow-up Study of Serologic Responses to 7-valent Pneumococcal Conjugated Vaccination and Opsonophagocytic Activities for Streptococcus Pneumoniae Among Patients With Human Immunodeficiency Virus Infection Unknown status NCT00885625 Phase 4
4 A Single-arm, International, Multi-center Trial Investigating the Efficacy and Safety of Ofatumumab Retreatment and Maintenance in CLL Patients Who Progressed Following Response or Stable Disease After Ofatumumab Treatment in Hx-CD20-406 Completed NCT00802737 Phase 4 Ofatumumab
5 A Multicenter Study to Confirm the Efficacy and Safety of Fludara i.v. (Fludarabine Phosphate, SH L 573), Administered in 6 Treatment Cycles (1 Treatment Cycle: 5-consecutive Day Dosing, Followed by an Observation Period of 23 Days) in Untreated Chronic Lymphocytic Leukemia Patients With Anemia and/or Thrombocytopenia Completed NCT00220311 Phase 4 Fludarabine Phosphate (Fludara)
6 The Duration of Humoral Immunity and the Memory Cell Function After Vaccination With 7-valent Pneumococcal Conjugate Vaccine in CLL Completed NCT00919321 Phase 4
7 Treatment of Chronic Lymphocytic Leukemia With the Use of an Antiviral Compound - a Proof of Principle Study Completed NCT01255644 Phase 4 Valganciclovir
8 A Randomized Study to Assess the Effect on Response Rate of MabThera (Rituximab) Added to a Standard Chemotherapy, Bendamustine or Chlorambucil, in Patients With Chronic Lymphocytic Leukemia Completed NCT01056510 Phase 4 bendamustine;chlorambucil;rituximab [MabThera/Rituxan]
9 The Effects of PROCRIT (Epoetin Alfa) on Hemoglobin, Symptom Distress, and Quality of Life During Chemotherapy in Lymphoma, Chronic Lymphocytic Leukemia or Multiple Myeloma Patients With Mild to Moderate Anemia Completed NCT00524407 Phase 4 Epoetin alfa
10 Evaluation of Allogeneic Marrow Transplants Depleted of T-Cells by CD34+ Selection in Patients Undergoing Transplantation With an Unrelated Matched or 1 Antigen Mismatched Donor or a 1 Antigen Mismatched Related Donor Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
11 Study Evaluating Rapid Infusion Rituximab in Patients With Autoimmune Diseases Completed NCT02040116 Phase 4 Rituximab Infusion
12 Alemtuzumab Versus Thymoglobulin Induction Therapy in Kidney and Pancreas Transplantation Completed NCT00331162 Phase 4 Alemtuzumab;Anti-Thymocyte Globulin
13 A Prospective, Multicenter, Open Label Single Arm Phase IV Clinical Trial to Assess Safety of ImbruvicaTM (Ibrutinib Capsules 140 mg) in Indian Patients With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion Recruiting NCT03190330 Phase 4 Ibrutinib 420 mg;Ibrutinib 560 mg
14 Prospective Study of Efficacy and Safety of RFC (Rituximab, Fludarabine, Cyclophosphamide) Regimen as a First-Line Therapy in Patients With B-Cell Chronic Lymphocytic Leukemia and Favorable Somatic Status Terminated NCT01271010 Phase 4 Cyclophosphamide;Fludarabine;Rituximab
15 Prospective Randomized Study to Compare Efficacy and Safety of RFC-Lite (Rituximab, Fludarabine, Cyclophosphamide) Regimen With LR (Rituximab, Chlorambucil) as a First-Line Therapy in Patients With B-Cell Chronic Lymphocytic Leukemia and Unfavorable Somatic Status Terminated NCT01283386 Phase 4 Chlorambucil;Cyclophosphamide;Fludarabine;Rituximab
16 Open Multicentric Study to Assess the Hematopoyetic Response in Terms of Increase of Hemoglobin Levels of Patients With Anemia Related to Non- Hodgkin Lymphoma, Chronic Lymphocytic Leukemia or Multiple Myeloma, Treated With Erythropoietin B (Recormon) Using Pre-filled Syringe With 30000 IU, as Well as to Quantify the Risk Factors of Anemia and Its Impact on Quality of Life Related to Treatment Terminated NCT02608060 Phase 4 Epoetin Beta
17 Low Dose Chlorambucil Maintenance Vs. No Treatment Following High-Dose Chlorambucil Induction In Patients With Advanced B-Chronic Lymphocytic Leukemia. A Randomized Phase III Study Of The EORTC LG (CLL-3) Unknown status NCT00017108 Phase 3 chlorambucil;cyclophosphamide;fludarabine phosphate
18 Study of Bendamustine Hydrochloride Injection in Previously Untreated Chronic Lymphocytic Leukemia Patients Unknown status NCT01657955 Phase 3 Bendamustine Hydrochloride Injection;Chlorambucil
19 Clinical Study of Chemoimmunotherapy With Fresh Frozen Plasma, High Dose Methylprednisolone and Rituximab for Ultra-high Risk Chronic Lymphocytic Leukemia Unknown status NCT01670812 Phase 3 FFP+HDMP+Rituximab
20 Randomized Controlled Study of Iron Supplementation to Support the Response to Recombinant Human Erythropoietin for the Treatment of Chemotherapy-Induced Anaemia Unknown status NCT00482716 Phase 3
21 A Randomized Phase III Trial Comparing the Combination of Fludarabine, BBR 2778 (Pixantrone) and Rituximab (FP-R) With the Combination of Fludarabine and Rituximab (F-R) in the Treatment of Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Unknown status NCT00551239 Phase 3 fludarabine phosphate;pixantrone dimaleate
22 Combination of Ibrutinib and As2O3 in the Treatment of CLL Unknown status NCT02757040 Phase 3 Ibrutinib combined with As2O3;ibrutinib
23 A Randomized Double-Blind Controlled Trial of Ketamine Versus Placebo in Conjunction With Best Pain Management in Neuropathic Pain in Cancer Patients Unknown status NCT01316744 Phase 3 ketamine hydrochloride
24 A Randomized Trial of Thymoglobulin to Prevent Chronic Graft Versus Host Disease in Patients Undergoing Hematopoietic Progenitor Cell Transplantation (HPCT) From Unrelated Donors Unknown status NCT01217723 Phase 3
25 A Randomized Phase III Study to Assess Intensification of the Conditioning Regimen for Allogenic Stem Cell Transplantation (ALLO-SCT) for Leukemia or Myelodysplastic Syndrome With a High Risk of Relapse Unknown status NCT00002989 Phase 3 busulfan;cyclophosphamide;idarubicin;melphalan
26 Phase III Randomized Trial of Fludarabine and Cyclophosphamide Versus Fludarabine for Previously Untreated Chronic Lymphocytic Leukemia Completed NCT00003764 Phase 3 cyclophosphamide;fludarabine phosphate
27 Randomized Phase III Trial Comparing Early Treatment With Fludarabine/Cyclophosphamide + Rituximab Versus Deferred Treatment in Untreated Binet Stage A Patients With CLL and High Risk of Progression Completed NCT00275054 Phase 3 Fludarabine;Cyclophosphamide
28 Chronic Lymphocytic Leukemia Trial 4: A Randomized Comparison of Chlorambucil, Fludarabine and Fludarabine Plus Cyclophosphamide Completed NCT00004218 Phase 3 chlorambucil;cyclophosphamide;doxorubicin hydrochloride;fludarabine phosphate;prednisolone;vincristine sulfate
29 Phase III Trial of Combined Immunochemotherapy With Fludarabine, Cyclophosphamide and Rituximab (FCR) Versus Chemotherapy With Fludarabine and Cyclophosphamide (FC) Alone in Patients With Previously Untreated Chronic Lymphocytic Leukaemia Completed NCT00281918 Phase 3 Rituximab;Cyclophosphamide;Fludarabine Phosphate
30 Prognostic Factors and Risk-Adapted Therapy in Patients With Early Stage Chronic Lymphocytic Leukemia Completed NCT00262782 Phase 3 Fludarabine
31 Fludarabine Versus Chlorambucil in First Line Therapy of Elderly Patients (More Than 65 Years) With Advanced Chronic Lymphocytic Leukemia Completed NCT00262795 Phase 3 Fludarabine;Chlorambucil
32 Bendamustine Versus Fludarabine as 2nd-line Treatment in Chronic Lymphocytic Leukemia, Stage BINET B+C / RAI II-IV Completed NCT01423032 Phase 2, Phase 3 bendamustine;Fludarabine
33 A Phase III, Open Label, Randomized Trial of Ofatumumab Added to Fludarabine-Cyclophosphamide vs. Fludarabine-Cyclophosphamide Combination in Subjects With Relapsed Chronic Lymphocytic Leukemia Completed NCT00824265 Phase 3 OFC Infusion;FC infusion
34 A Randomized Phase III Trial to Determine Whether Conjugated Pneumococcal Vaccine Can Improve the Immune Responsiveness Compared to Polyclonal Pneumococcal Vaccine in Patients With Untreated Chronic Lymphocytic Leukemia Completed NCT01892618 Phase 3 Prevenar 13;Pneumovax
35 A Prospective, Randomized, Open Label, Phase III Trial of Fludarabine, Cyclophosphamide, and Rituximab vs. Pentostatin, Cyclophosphamide, and Rituximab in Previously Untreated or Treated B-cell Chronic Lymphocytic Leukemia Completed NCT00254163 Phase 3 Fludarabine;Cyclophosphamide;Rituximab;Pentostatin
36 Open-label, Multicenter, Randomized, Comparative, Phase III Study to Evaluate the Efficacy and Safety of FCR vs. FC Alone in Previously Treated Patients With CD20 Positive B-cell CLL Completed NCT00090051 Phase 3 Rituximab;Fludarabine Phosphate;Cyclophosphamide
37 Darbepoetin Alfa in Patients With Chronic Lymphocytic Leukemia and Comorbidity Completed NCT00281892 Phase 3 Fludarabine mono
38 A Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Completed NCT01578707 Phase 3 ofatumumab;ibrutinib
39 Fludarabine Versus Fludarabine Plus Cyclophosphamide in First Line Therapy of Younger Patients (Up to 65 Years) With Advanced Chronic Lymphocytic Leukemia (CLL) Completed NCT00276848 Phase 3 Fludarabine plus Cyclophosphamide;Fludarabine
40 Phase III Trial of Combined Immunochemotherapy With Fludarabine, Cyclophosphamide and Rituximab (FCR) Versus Bendamustine and Rituximab (BR) in Patients With Previously Untreated Chronic Lymphocytic Leukaemia Completed NCT00769522 Phase 3 Bendamustine;Cyclophosphamide;Fludarabine
41 Randomized Phase-III Trial Comparing Fludarabine and Cyclophosphamide Plus Rituximab (FCR) to FC and MabCampath (FCCam) for Previously Untreated Fit Patients With Chronic Lymphocytic Leukemia (CLL) Completed NCT00564512 Phase 3 cyclophosphamide;fludarabine
42 Randomized Phase III Trial Evaluating the Role of Autologous Stem Cell Transplantation in Previously Untreated Patients With Stage B and C Chronic Lymphocytic Leukemia Completed NCT00931645 Phase 3
43 A Phase III Study to Evaluate the Efficacy and Safety of Front-Line Therapy With Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Chronic Lymphocytic Leukemia Completed NCT00046683 Phase 3 alemtuzumab
44 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia Completed NCT01569295 Phase 3 Idelalisib;Rituximab;Bendamustine;Placebo to match idelalisib
45 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia Completed NCT01539512 Phase 3 Idelalisib;Rituximab;Placebo to match idelalisib
46 A Phase 3 Study to Evaluate the Efficacy and Safety of Dinaciclib or Ofatumumab in Subjects With Refractory Chronic Lymphocytic Leukemia Completed NCT01580228 Phase 3 Dinaciclib;Ofatumumab
47 A Randomized, Multicenter, Open-Label, Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor PCI-32765 (Ibrutinib) Versus Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Completed NCT01973387 Phase 3 Rituximab;Ibrutinib
48 Randomized, Double-blind, Placebo-controlled Phase 3 Study of Ibrutinib, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Combination With Bendamustine and Rituximab (BR) in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Completed NCT01611090 Phase 3 Ibrutinib;Bendamustine hydrochloride;Rituximab;Placebo
49 A Multicenter, Open-Label, Single-Arm, Phase IIIb, International Study Evaluating the Safety of Obinutuzumab Alone or in Combination With Chemotherapy in Patients With Previously Untreated or Relapsed/Refractory Chronic Lymphocytic Leukemia Completed NCT01905943 Phase 3 Bendamustine;Chlorambucil;Cyclophosphamide;Fludarabine;Obinutuzumab
50 Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Versus Chlorambucil in Patients 65 Years or Older With Treatment-naive Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Completed NCT01722487 Phase 3 Ibrutinib;Chlorambucil

Search NIH Clinical Center for Leukemia, B-Cell, Chronic

Inferred drug relations via UMLS 72 / NDF-RT 51 :


alemtuzumab
Chlorambucil
Cladribine
Cyclophosphamide
etoposide phosphate
fludarabine
Fludarabine phosphate
Ibrutinib
Ifosfamide
Immunoglobulins, Intravenous
mercaptopurine
pegaspargase
Uracil Mustard

Genetic Tests for Leukemia, B-Cell, Chronic

Anatomical Context for Leukemia, B-Cell, Chronic

MalaCards organs/tissues related to Leukemia, B-Cell, Chronic:

41
B Cells, T Cells, Bone, Bone Marrow, Myeloid, Lymph Node, Testes

Publications for Leukemia, B-Cell, Chronic

Articles related to Leukemia, B-Cell, Chronic:

(show top 50) (show all 15615)
# Title Authors PMID Year
1
Expression of BTK/p-BTK is different between CD5+ and CD5- B lymphocytes from Autoimmune Hemolytic Anemia/Evans syndromes. 38
31392938 2019
2
CD markers variations in chronic lymphocytic leukemia: New insights into prognosis. 38
31049958 2019
3
First Case of Transformation of Immunoglobulin Heavy Chain Variable-Mutated Chronic Lymphocytic Leukemia Into Chronic Myeloid Leukemia. 38
31240887 2019
4
TRIM13 inhibited cell proliferation and induced cell apoptosis by regulating NF-κB pathway in non-small-cell lung carcinoma cells. 38
31357025 2019
5
STAT3-induced SMYD3 transcription enhances chronic lymphocytic leukemia cell growth in vitro and in vivo. 38
31218443 2019
6
Idelalisib for optimized CD19-specific chimeric antigen receptor T cells in chronic lymphocytic leukemia patients. 38
30737788 2019
7
Chronic lymphocytic leukemia patients with HLA-B27 referred for allogeneic hematopoietic stem cell transplantation do not have worse outcomes: Results of a population-based case series analysis in British Columbia, Canada. 38
31325731 2019
8
Marek's Disease Virus-Encoded MicroRNA 155 Ortholog Critical for the Induction of Lymphomas Is Not Essential for the Proliferation of Transformed Cell Lines. 38
31189706 2019
9
Cerebral aspergillosis in a patient on ibrutinib therapy-A predisposition not to overlook. 38
30045683 2019
10
Rituximab dosing in hematological malignancies: an old question, revisited. 38
30899984 2019
11
Early Events in Lymphoid Neoplasms and Indolent Follicular Lymphomas. 38
31352984 2019
12
Merkel cell carcinoma of the eyelid: A review. 38
30871952 2019
13
Entinostat combined with Fludarabine synergistically enhances the induction of apoptosis in TP53 mutated CLL cells via the HDAC1/HO-1 pathway. 38
31226417 2019
14
Blockage of autophagic flux is associated with lymphocytosis and higher percentage of tumoral cells in chronic lymphocytic leukemia of B cells. 38
30680609 2019
15
Overlapped differentially expressed genes between acute lymphoblastic leukemia and chronic lymphocytic leukemia revealed potential key genes and pathways involved in leukemia. 38
31081970 2019
16
An emerging trend of rapid increase of leukemia but not all cancers in the aging population in the United States. 38
31427635 2019
17
Prevalence of BTK and PLCG2 mutations in a real-life CLL cohort still on ibrutinib after 3 years: a FILO group study. 38
31243043 2019
18
Long telomeres and cancer risk: the price of cellular immortality. 38
31380804 2019
19
ROR1-targeted delivery of miR-29b induces cell cycle arrest and therapeutic benefit in vivo in a CLL mouse model. 38
31151986 2019
20
The impacts of zanubrutinib on immune cells in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. 38
31420873 2019
21
Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemia. 38
31371416 2019
22
Distinctive IGHV gene usage and stereotyped receptors in South American patients with chronic lymphocytic leukemia. 38
31373034 2019
23
Predicting the outcome of patients with chronic lymphocytic leukemia: Progress and uncertainty. 38
31381130 2019
24
State-of-the-art for CAR T-cell therapy for chronic lymphocytic leukemia in 2019. 38
31370892 2019
25
Association of elevated serumfree light chains with chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis. 38
31383849 2019
26
Illness Perceptions in Chronic Lymphocytic Leukemia: Testing Leventhal's Self-regulatory Model. 38
30590383 2019
27
Peripheral T-Cell Lymphoma Arising in Patients With Chronic Lymphocytic Leukemia. 38
31433844 2019
28
Clinical significance of DNA methylation in chronic lymphocytic leukemia patients: results from 3 UK clinical trials. 38
31434681 2019
29
Insight into genetic predisposition to chronic lymphocytic leukemia from integrative epigenomics. 38
31399598 2019
30
Having co-morbid cardiovascular disease at time of cancer diagnosis: already one step behind when it comes to HRQoL? 38
31389275 2019
31
Nonmyeloablative TLI-ATG conditioning for allogeneic transplantation: mature follow-up from a large single-center cohort. 38
31427277 2019
32
IL-33 Is a Cell-Intrinsic Regulator of Fitness during Early B Cell Development. 38
31391233 2019
33
Pharmacokinetics of the BCL-2 Inhibitor Venetoclax in Subjects with Hepatic Impairment. 38
30949874 2019
34
Chromosomal microarray analysis is superior in identifying cryptic aberrations in patients with acute lymphoblastic leukemia at diagnosis/relapse as a single assay. 38
31112375 2019
35
Genetic overlap between autoimmune diseases and non-Hodgkin lymphoma subtypes. 38
31407831 2019
36
Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia. 38
31365801 2019
37
Effect of Chronic Hematologic Malignancies on In-Hospital Outcomes of Patients With ST-Segment Elevation Myocardial Infarction. 38
31196560 2019
38
IGF1R as druggable target mediating PI3K-δ inhibitor resistance in a murine model of chronic lymphocytic leukemia. 38
31010847 2019
39
Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report. 38
31253630 2019
40
Increased autocrine interleukin-6 production is significantly associated with worse clinical outcome in patients with chronic lymphocytic leukemia. 38
30623437 2019
41
Cirmtuzumab Blocks Wnt5a/ROR1-Stimulation Of NF-κB To Repress Autocrine STAT3-Activation In Chronic Lymphocytic Leukemia. 38
31409670 2019
42
Abnormalities in chemokine receptor recycling in chronic lymphocytic leukemia. 38
30830241 2019
43
Targeting BCL2 in Chronic Lymphocytic Leukemia and Other Hematologic Malignancies. 38
31313099 2019
44
Examination of clonal evolution in chronic lymphocytic leukemia. 38
31375939 2019
45
Exploring a Future for PI3K Inhibitors in Chronic Lymphocytic Leukemia. 38
31203516 2019
46
Apoptotic resistance in chronic lymphocytic leukemia and therapeutic perspectives. 38
30935269 2019
47
MDM2 Oncogene Copy Number Alterations in Chronic Lymphocytic Leukemia 38
31117332 2019
48
CD200 and prognosis in chronic lymphocytic leukemia: Conflicting results. 38
31212087 2019
49
Meat, fish, dairy products and risk of hematological malignancies in adults - a systematic review and meta-analysis of prospective studies. 38
30912696 2019
50
Recommendations for ibrutinib treatment in patients with atrial fibrillation and/or elevated cardiovascular risk. 38
31414181 2019

Variations for Leukemia, B-Cell, Chronic

Expression for Leukemia, B-Cell, Chronic

Search GEO for disease gene expression data for Leukemia, B-Cell, Chronic.

Pathways for Leukemia, B-Cell, Chronic

GO Terms for Leukemia, B-Cell, Chronic

Sources for Leukemia, B-Cell, Chronic

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....